Phaseline

Targets › CDH3

CDH3 (Cadherin-3): drug programs, companies and trials

2 programs from 2 companies in 7 trials: 4 Phase 2, 3 Phase 1; Oncology; next expected readout Apr 2027.

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, P22223)

Open in Phaseline: the race on CDH3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX
ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1Phase 2Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast CarcinomaApr 2027
Biocity BiopharmaceuticsBC3195
anti-CDH3 antibody-drug conjugate with MMAE payload
CDH3Phase 1Advanced Cancer; Locally Advanced or Metastatic Solid TumorsApr 2027

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 (2) Advanced Cancer (1) Locally Advanced or Metastatic Solid Tumors (1) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1)

Modalities

small molecule (1), mixed (1)

Companies

Biocity Biopharmaceutics (1) University of Washington (1)

Related targets

ENG (1) YBX1 (1) SOX2 (1) MDM2 (1) CD105 (1) YB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.